Has experienced documented objective radiographic or clinical disease progression during or after receiving more than  line of therapy.
Objective, documented evidence of disease progression on study entry
Participants must have evidence of disease progression within  months prior to study entry
Radiological or objective evidence of recurrence or progression on or after the last systemic therapy prior to enrollment
Patients with NHL must have objective, documented evidence of disease prior to study entry
Previous diagnosis of MM with objective evidence of measurable disease
Have documented objective radiographic progression after stopping treatment with first-line therapy; Note: the same image acquisition and processing parameters should be used throughout the study for a given subject
Progression of disease must be documented prior to study entry
Prior radiation performed to areas of measurable disease ? four weeks of study entry unless there is documented evidence of disease progression.
Documented disease progression at study entry
Radiologic/objective evidence of recurrence or progression to the most recent systemic therapy for breast cancer
Documented objective radiographic or clinical disease progression on two previous lines of standard therapy
Target lesion previously embolized, perfused, or irradiated without objective evidence of progression before start of therapy to be considered for response assessment
Documented progressive (clinical and/or objective) disease after the most recent systemic therapy regimen
Objective evidence of disease progression (clinical or radiological) during or after at least  (V Wildtype) or at least  (V mutation positive) prior treatment regimens
Evidence of objective disease. A measurable lesion is not necessary.
Evidence of disease progression at study entry.
Progression of disease despite androgen ablation shown by objective, documented evidence of disease progression (excluding PSA).
Objective documented evidence of disease progression at study entry
Objective evidence of disease progression on study entry
Objective evidence of disease progression on study entry